Alessandro Del Conte

Aviano, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Liquid Biopsy Monitoring in BRAF V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020).

Liquid Biopsy Monitoring in BRAF V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020).

Journal: JCO precision oncology

Published: June 12, 2026

BRAF class II-III mutations in NSCLC: a single center experience.

BRAF class II-III mutations in NSCLC: a single center experience.

Journal: Frontiers in oncology

Published: October 02, 2025

A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy-The Predict & Prevent Project.

A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy-The Predict & Prevent Project.

Journal: Healthcare (Basel, Switzerland)

Published: September 15, 2025

Vitamins and minerals and their role in cancer: a comprehensive review.

Vitamins and minerals and their role in cancer: a comprehensive review.

Journal: Frontiers in nutrition

Published: August 15, 2025

Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.

Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.

Journal: Cancer treatment and research communications

Published: July 22, 2025

Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies.

Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies.

Journal: Cancers

Published: February 11, 2025

Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches.

Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches.

Journal: International journal of molecular sciences

Published: December 20, 2024

EML4-ALK: Update on ALK Inhibitors.

EML4-ALK: Update on ALK Inhibitors.

Journal: International journal of molecular sciences

Published: December 04, 2024

Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer.

Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer.

Journal: International journal of molecular sciences

Published: November 22, 2024

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.

Journal: International journal of molecular sciences

Published: October 31, 2024

Targeted Therapy in Mesotheliomas: Uphill All the Way.

Targeted Therapy in Mesotheliomas: Uphill All the Way.

Journal: Cancers

Published: April 06, 2024

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.

Journal: The oncologist

Published: October 17, 2023

Showing 1-12 of 59

Last Updated: 09/26/2026